Researchers created an 8-item questionnaire to screen for problematic medical cannabis use focused on negative consequences
A new 8-item Medicinal Cannabis Negative Consequences Scale (MCNCS) was developed and validated among 390 chronic pain patients, defining problematic medical cannabis use by its negative physiological, social, emotional, and functional consequences rather than dependence criteria.
Quick Facts
What This Study Found
Starting from 36 items compiled from opioid screening tools, cannabis use disorder instruments, and patient interviews, the researchers refined to an 8-item scale with excellent internal consistency (alpha 0.929). Items focused predominantly on negative consequences rather than dependence symptoms. The scale correlated significantly with anxiety and low quality of life.
Key Numbers
390 chronic pain patients. Started with 36 items from 3 sources. Final 8-item scale. Internal consistency alpha = 0.929. Named MCNCS (Medicinal Cannabis Negative Consequences Scale). Significantly correlated with anxiety and low quality of life.
How They Did This
Scale development using 390 American chronic pain patients with medical cannabis cards. Items rated on 5-point frequency scale. Multi-group measurement invariance comparison using alcohol problems and depression as external indicators. Content validation from multiple sources.
Why This Research Matters
Existing cannabis use disorder screening tools were designed for recreational use and may overcount medical patients who show physical dependence without actual problems. This tool redefines "problematic" medical cannabis use around consequences rather than dependence criteria.
The Bigger Picture
As medical cannabis expands, distinguishing therapeutic dependence from problematic use is crucial. A tool that focuses on whether cannabis use causes actual harm rather than simply flagging dependence could prevent unnecessary treatment while catching genuinely problematic patterns.
What This Study Doesn't Tell Us
Self-identified patients via online recruitment; may not represent all medical cannabis users. American sample only. Preliminary validation needs replication. No longitudinal data on whether MCNCS scores predict future adverse outcomes. Scale does not include physician assessment.
Questions This Raises
- ?At what MCNCS score should clinicians intervene?
- ?How does this scale perform compared to standard CUD screening in medical cannabis populations?
Trust & Context
- Key Stat:
- 8-item scale with 0.929 reliability distinguishes problematic from therapeutic use
- Evidence Grade:
- Rigorous psychometric development with appropriate validation methods, though preliminary and requires replication in diverse populations.
- Study Age:
- 2024 study
- Original Title:
- Conceptualizing problematic use of medicinal Cannabis: Development and preliminary validation of a brief screening questionnaire.
- Published In:
- Addictive behaviors, 158, 108122 (2024)
- Authors:
- Feingold, Daniel(12), Gliksberg, Or(4), Brill, Silviu(4), Amit, Ben H, Lev-Ran, Shaul, Kushnir, Talma, Sznitman, Sharon R
- Database ID:
- RTHC-05306
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Why not use regular cannabis addiction screening tools?
Standard CUD tools were designed for recreational use and flag physical dependence (tolerance, withdrawal) as problematic. Medical cannabis patients may develop physical dependence as part of legitimate treatment without experiencing actual negative consequences.
What kind of negative consequences does the scale measure?
The final items covered physiological, social, emotional, and functional consequences of medical cannabis use, such as impaired daily functioning, relationship problems, and emotional disturbance, rather than dependence symptoms like tolerance.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05306APA
Feingold, Daniel; Gliksberg, Or; Brill, Silviu; Amit, Ben H; Lev-Ran, Shaul; Kushnir, Talma; Sznitman, Sharon R. (2024). Conceptualizing problematic use of medicinal Cannabis: Development and preliminary validation of a brief screening questionnaire.. Addictive behaviors, 158, 108122. https://doi.org/10.1016/j.addbeh.2024.108122
MLA
Feingold, Daniel, et al. "Conceptualizing problematic use of medicinal Cannabis: Development and preliminary validation of a brief screening questionnaire.." Addictive behaviors, 2024. https://doi.org/10.1016/j.addbeh.2024.108122
RethinkTHC
RethinkTHC Research Database. "Conceptualizing problematic use of medicinal Cannabis: Devel..." RTHC-05306. Retrieved from https://rethinkthc.com/research/feingold-2024-conceptualizing-problematic-use-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.